Lupin has launched an authorized generic version of Ravicti (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL is indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
